Alnylam Pharmaceuticals (ALNY) Competitors

$293.45 +1.97 (+0.68%)

Closing price 04:00 PM Eastern

Extended Trading

$293.31 -0.14 (-0.05%)

As of 07:04 PM Eastern

ALNY vs. VRTX, REGN, BIIB, UTHR, and INCY

Should you buy Alnylam Pharmaceuticals stock or one of its competitors? MarketBeat compares Alnylam Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Alnylam Pharmaceuticals include Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), United Therapeutics (UTHR), and Incyte (INCY). These companies are all part of the "biotechnology" industry.

How does Alnylam Pharmaceuticals compare to Vertex Pharmaceuticals?

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, media sentiment, valuation and profitability.

Alnylam Pharmaceuticals has a beta of 0.31, meaning that its stock price is 69% less volatile than the broader market. Comparatively, Vertex Pharmaceuticals has a beta of 0.3, meaning that its stock price is 70% less volatile than the broader market.

In the previous week, Vertex Pharmaceuticals had 11 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 31 mentions for Vertex Pharmaceuticals and 20 mentions for Alnylam Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 0.98 beat Alnylam Pharmaceuticals' score of 0.42 indicating that Vertex Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alnylam Pharmaceuticals	5 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vertex Pharmaceuticals	17 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Alnylam Pharmaceuticals currently has a consensus price target of $471.96, suggesting a potential upside of 60.83%. Vertex Pharmaceuticals has a consensus price target of $555.17, suggesting a potential upside of 23.26%. Given Alnylam Pharmaceuticals' higher possible upside, analysts plainly believe Alnylam Pharmaceuticals is more favorable than Vertex Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.81
Vertex Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.85

93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 91.0% of Vertex Pharmaceuticals shares are held by institutional investors. 0.9% of Alnylam Pharmaceuticals shares are held by insiders. Comparatively, 0.2% of Vertex Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Vertex Pharmaceuticals has a net margin of 35.51% compared to Alnylam Pharmaceuticals' net margin of 11.72%. Alnylam Pharmaceuticals' return on equity of 85.76% beat Vertex Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	11.72%	85.76%	10.32%
Vertex Pharmaceuticals	35.51%	23.86%	17.13%

Vertex Pharmaceuticals has higher revenue and earnings than Alnylam Pharmaceuticals. Vertex Pharmaceuticals is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$3.71B	10.55	$313.75M	$3.66	80.18
Vertex Pharmaceuticals	$12.00B	9.53	$3.95B	$16.86	26.71

Summary

Vertex Pharmaceuticals beats Alnylam Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Alnylam Pharmaceuticals compare to Regeneron Pharmaceuticals?

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, media sentiment, valuation and profitability.

Alnylam Pharmaceuticals has a beta of 0.31, meaning that its stock price is 69% less volatile than the broader market. Comparatively, Regeneron Pharmaceuticals has a beta of 0.3, meaning that its stock price is 70% less volatile than the broader market.

93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 83.3% of Regeneron Pharmaceuticals shares are held by institutional investors. 0.9% of Alnylam Pharmaceuticals shares are held by insiders. Comparatively, 7.0% of Regeneron Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Regeneron Pharmaceuticals has a net margin of 29.65% compared to Alnylam Pharmaceuticals' net margin of 11.72%. Alnylam Pharmaceuticals' return on equity of 85.76% beat Regeneron Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	11.72%	85.76%	10.32%
Regeneron Pharmaceuticals	29.65%	13.16%	10.17%

Regeneron Pharmaceuticals has higher revenue and earnings than Alnylam Pharmaceuticals. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$3.71B	10.55	$313.75M	$3.66	80.18
Regeneron Pharmaceuticals	$14.34B	5.25	$4.50B	$41.04	17.37

In the previous week, Alnylam Pharmaceuticals had 3 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 20 mentions for Alnylam Pharmaceuticals and 17 mentions for Regeneron Pharmaceuticals. Regeneron Pharmaceuticals' average media sentiment score of 1.22 beat Alnylam Pharmaceuticals' score of 0.42 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alnylam Pharmaceuticals	5 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Regeneron Pharmaceuticals	12 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Alnylam Pharmaceuticals currently has a consensus price target of $471.96, suggesting a potential upside of 60.83%. Regeneron Pharmaceuticals has a consensus price target of $826.59, suggesting a potential upside of 15.95%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Alnylam Pharmaceuticals is more favorable than Regeneron Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.81
Regeneron Pharmaceuticals	0 Sell rating(s)	8 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.77

Summary

Alnylam Pharmaceuticals beats Regeneron Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Alnylam Pharmaceuticals compare to Biogen?

Biogen (NASDAQ:BIIB) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, media sentiment, valuation and risk.

Biogen has a beta of 0.19, indicating that its stock price is 81% less volatile than the broader market. Comparatively, Alnylam Pharmaceuticals has a beta of 0.31, indicating that its stock price is 69% less volatile than the broader market.

Biogen presently has a consensus target price of $214.23, indicating a potential upside of 11.95%. Alnylam Pharmaceuticals has a consensus target price of $471.96, indicating a potential upside of 60.83%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Alnylam Pharmaceuticals is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	1 Sell rating(s)	13 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.50
Alnylam Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.81

Biogen has higher revenue and earnings than Alnylam Pharmaceuticals. Biogen is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$9.89B	2.86	$1.29B	$9.32	20.53
Alnylam Pharmaceuticals	$3.71B	10.55	$313.75M	$3.66	80.18

Biogen has a net margin of 13.81% compared to Alnylam Pharmaceuticals' net margin of 11.72%. Alnylam Pharmaceuticals' return on equity of 85.76% beat Biogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	13.81%	12.83%	8.01%
Alnylam Pharmaceuticals	11.72%	85.76%	10.32%

87.9% of Biogen shares are held by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. 0.3% of Biogen shares are held by company insiders. Comparatively, 0.9% of Alnylam Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Biogen had 27 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 47 mentions for Biogen and 20 mentions for Alnylam Pharmaceuticals. Biogen's average media sentiment score of 0.91 beat Alnylam Pharmaceuticals' score of 0.42 indicating that Biogen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	22 Very Positive mention(s)	9 Positive mention(s)	12 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Alnylam Pharmaceuticals	5 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Alnylam Pharmaceuticals beats Biogen on 10 of the 16 factors compared between the two stocks.

How does Alnylam Pharmaceuticals compare to United Therapeutics?

Alnylam Pharmaceuticals (NASDAQ:ALNY) and United Therapeutics (NASDAQ:UTHR) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.

Alnylam Pharmaceuticals has a beta of 0.31, meaning that its stock price is 69% less volatile than the broader market. Comparatively, United Therapeutics has a beta of 0.6, meaning that its stock price is 40% less volatile than the broader market.

United Therapeutics has a net margin of 40.62% compared to Alnylam Pharmaceuticals' net margin of 11.72%. Alnylam Pharmaceuticals' return on equity of 85.76% beat United Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	11.72%	85.76%	10.32%
United Therapeutics	40.62%	19.24%	17.25%

In the previous week, United Therapeutics had 7 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 27 mentions for United Therapeutics and 20 mentions for Alnylam Pharmaceuticals. Alnylam Pharmaceuticals' average media sentiment score of 0.42 beat United Therapeutics' score of 0.39 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alnylam Pharmaceuticals	5 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
United Therapeutics	12 Very Positive mention(s)	5 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Alnylam Pharmaceuticals presently has a consensus target price of $471.96, indicating a potential upside of 60.83%. United Therapeutics has a consensus target price of $619.42, indicating a potential upside of 7.58%. Given Alnylam Pharmaceuticals' higher possible upside, equities research analysts plainly believe Alnylam Pharmaceuticals is more favorable than United Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.81
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85

United Therapeutics has lower revenue, but higher earnings than Alnylam Pharmaceuticals. United Therapeutics is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$3.71B	10.55	$313.75M	$3.66	80.18
United Therapeutics	$3.18B	7.68	$1.33B	$27.09	21.25

93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 94.1% of United Therapeutics shares are owned by institutional investors. 0.9% of Alnylam Pharmaceuticals shares are owned by insiders. Comparatively, 8.6% of United Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

United Therapeutics beats Alnylam Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Alnylam Pharmaceuticals compare to Incyte?

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Incyte (NASDAQ:INCY) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk and dividends.

Incyte has a net margin of 26.71% compared to Alnylam Pharmaceuticals' net margin of 11.72%. Alnylam Pharmaceuticals' return on equity of 85.76% beat Incyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	11.72%	85.76%	10.32%
Incyte	26.71%	26.66%	19.77%

Alnylam Pharmaceuticals has a beta of 0.31, indicating that its stock price is 69% less volatile than the broader market. Comparatively, Incyte has a beta of 0.79, indicating that its stock price is 21% less volatile than the broader market.

93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 97.0% of Incyte shares are owned by institutional investors. 0.9% of Alnylam Pharmaceuticals shares are owned by company insiders. Comparatively, 16.2% of Incyte shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Alnylam Pharmaceuticals had 9 more articles in the media than Incyte. MarketBeat recorded 20 mentions for Alnylam Pharmaceuticals and 11 mentions for Incyte. Incyte's average media sentiment score of 0.78 beat Alnylam Pharmaceuticals' score of 0.42 indicating that Incyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alnylam Pharmaceuticals	5 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Incyte	4 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Alnylam Pharmaceuticals presently has a consensus target price of $471.96, suggesting a potential upside of 60.83%. Incyte has a consensus target price of $104.26, suggesting a potential upside of 6.79%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Alnylam Pharmaceuticals is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.81
Incyte	1 Sell rating(s)	10 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.43

Incyte has higher revenue and earnings than Alnylam Pharmaceuticals. Incyte is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$3.71B	10.55	$313.75M	$3.66	80.18
Incyte	$5.14B	3.79	$1.29B	$7.08	13.79

Summary

Incyte beats Alnylam Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

Get Alnylam Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALNY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALNY vs. The Competition

Export

Metric	Alnylam Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$38.92B	$3.42B	$6.34B	$12.38B
Dividend Yield	N/A	2.31%	2.80%	5.35%
P/E Ratio	80.18	18.47	20.90	25.62
Price / Sales	10.55	295.31	549.01	77.56
Price / Cash	104.25	125.29	43.26	56.33
Price / Book	36.45	6.93	9.93	6.96
Net Income	$313.75M	$24.11M	$3.55B	$333.52M
7 Day Performance	-0.83%	0.08%	-0.33%	0.45%
1 Month Performance	-13.54%	0.84%	1.34%	4.06%
1 Year Performance	9.68%	78.10%	41.10%	36.24%

Alnylam Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALNY Alnylam Pharmaceuticals	4.5147 of 5 stars	$293.45 +0.7%	$471.96 +60.8%	+9.2%	$38.92B	$3.71B	80.18	2,770
VRTX Vertex Pharmaceuticals	4.3323 of 5 stars	$435.17 +1.2%	$555.17 +27.6%	+4.9%	$109.09B	$12.00B	25.81	6,400	Insider Trade Analyst Revision
REGN Regeneron Pharmaceuticals	4.4246 of 5 stars	$712.77 -0.3%	$826.59 +16.0%	+25.4%	$75.58B	$14.34B	17.37	15,410	Positive News
BIIB Biogen	3.8759 of 5 stars	$197.95 +2.3%	$214.23 +8.2%	+66.1%	$28.56B	$9.89B	21.24	7,500	Trending News Analyst Forecast
UTHR United Therapeutics	3.6011 of 5 stars	$569.88 +0.9%	$619.42 +8.7%	+88.1%	$23.98B	$3.18B	21.04	1,400	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALNY) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alnylam Pharmaceuticals (ALNY) Competitors

ALNY vs. VRTX, REGN, BIIB, UTHR, and INCY

How does Alnylam Pharmaceuticals compare to Vertex Pharmaceuticals?

Summary

How does Alnylam Pharmaceuticals compare to Regeneron Pharmaceuticals?

Summary

How does Alnylam Pharmaceuticals compare to Biogen?

Summary

How does Alnylam Pharmaceuticals compare to United Therapeutics?

Summary

How does Alnylam Pharmaceuticals compare to Incyte?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALNY vs. The Competition

Alnylam Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alnylam Pharmaceuticals (ALNY) Competitors

ALNY vs. VRTX, REGN, BIIB, UTHR, and INCY

How does Alnylam Pharmaceuticals compare to Vertex Pharmaceuticals?

Which has more volatility & risk, ALNY or VRTX?

Does the media prefer ALNY or VRTX?

Do analysts rate ALNY or VRTX?

Do institutionals & insiders believe in ALNY or VRTX?

Is ALNY or VRTX more profitable?

Which has stronger valuation and earnings, ALNY or VRTX?

Summary

How does Alnylam Pharmaceuticals compare to Regeneron Pharmaceuticals?

Which has more volatility & risk, ALNY or REGN?

Do institutionals & insiders believe in ALNY or REGN?

Is ALNY or REGN more profitable?

Which has stronger valuation and earnings, ALNY or REGN?

Does the media prefer ALNY or REGN?

Do analysts rate ALNY or REGN?

Summary

How does Alnylam Pharmaceuticals compare to Biogen?

Which has more risk and volatility, BIIB or ALNY?

Do analysts recommend BIIB or ALNY?

Which has better valuation and earnings, BIIB or ALNY?

Is BIIB or ALNY more profitable?

Do institutionals and insiders believe in BIIB or ALNY?

Does the media favor BIIB or ALNY?

Summary

How does Alnylam Pharmaceuticals compare to United Therapeutics?

Which has more volatility and risk, ALNY or UTHR?

Is ALNY or UTHR more profitable?

Does the media refer more to ALNY or UTHR?

Do analysts rate ALNY or UTHR?

Which has stronger earnings & valuation, ALNY or UTHR?

Do insiders & institutionals believe in ALNY or UTHR?

Summary

How does Alnylam Pharmaceuticals compare to Incyte?

Is ALNY or INCY more profitable?

Which has more volatility & risk, ALNY or INCY?

Do insiders and institutionals have more ownership in ALNY or INCY?

Does the media refer more to ALNY or INCY?

Do analysts rate ALNY or INCY?

Which has higher earnings & valuation, ALNY or INCY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALNY vs. The Competition

Alnylam Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools